Kristt D A, Reedy E, Yarden Y
Department of Pathology, University of Maryland School of Medicine, Baltimore.
Neurosurgery. 1993 Jul;33(1):106-15. doi: 10.1227/00006123-199307000-00017.
The purpose of this study was to determine if the expression of receptor tyrosine kinases would distinguish astrocytosis from astrocytoma. Because the expression of this family of receptor proteins is greater in higher-grade tumors, a graded series of both reactive and neoplastic astrocytic lesions in humans was evaluated. The reactive processes included both mild gliosis and severe (intense) gliosis. The two immunocytochemically detected membrane receptor proteins, p145 and p185, are those encoded by the kit and neu genes, respectively. Semi-quantitative assessments were made independently for the frequency and intensity of astrocytic immunostaining together with corollary immunocytochemical staining to detect glial fibrillary acidic protein. It was found that both mild gliosis and low-grade astrocytomas only minimally express these receptors. In contrast, severe gliosis and high-grade neoplasms consistently express these receptors at much higher levels. In both astrocytosis and astrocytomas, a cell with abundant perikaryal cytoplasm is most likely to be immunoreactive, often with dense reaction product concentrated at the periphery of the somal cytoplasm. The extent and pattern of immunoreactivity in high-grade astrocytomas preclude the interpretation that all immunoreactive cells were merely reactive astrocytes. We conclude that the expression of these receptors per se does not differentiate astrocytic neoplasia from reactive astrocytosis. Second, we conclude that immunocytochemically detectable levels of neu or kit receptor expression is not constitutive in normal astrocytes and in some stages of astrocytic neoplasia. On the basis of these findings, we speculate that some neoplastic astrocytes maintain and manifest the capacity to respond to transitory exogenous stimuli, as do reactive astrocytes. This reaction could include the elaboration of receptor tyrosine kinases. Alternatively, even if the function of these receptors in gliosis differs from that in gliomas, the common expression could still reflect an "active" state shared by astrocytes in these two processes.
本研究的目的是确定受体酪氨酸激酶的表达是否能区分星形细胞增多症和星形细胞瘤。由于该家族受体蛋白在高级别肿瘤中的表达更高,因此对人类反应性和肿瘤性星形细胞病变的分级系列进行了评估。反应性过程包括轻度胶质增生和重度(强烈)胶质增生。免疫细胞化学检测到的两种膜受体蛋白p145和p185分别由kit和neu基因编码。对星形细胞免疫染色的频率和强度以及用于检测胶质纤维酸性蛋白的配套免疫细胞化学染色进行了独立的半定量评估。结果发现,轻度胶质增生和低级别星形细胞瘤仅极少表达这些受体。相反,重度胶质增生和高级别肿瘤始终以高得多的水平表达这些受体。在星形细胞增多症和星形细胞瘤中,胞核周围细胞质丰富的细胞最有可能具有免疫反应性,通常在细胞质体周边有密集的反应产物。高级别星形细胞瘤中免疫反应性的程度和模式排除了所有免疫反应性细胞仅仅是反应性星形胶质细胞的解释。我们得出结论,这些受体本身的表达并不能区分星形细胞肿瘤与反应性星形细胞增多症。其次,我们得出结论,在正常星形胶质细胞和星形细胞肿瘤的某些阶段,免疫细胞化学可检测到的neu或kit受体表达水平并非组成性表达。基于这些发现,我们推测一些肿瘤性星形胶质细胞保持并表现出像反应性星形胶质细胞一样对短暂外源性刺激作出反应的能力。这种反应可能包括受体酪氨酸激酶的产生。或者,即使这些受体在胶质增生中的功能与在胶质瘤中的功能不同,共同表达仍可能反映这两个过程中星形胶质细胞共有的“活跃”状态。